267243-64-1 Usage
Description
N-(3-chloro-4-fluorophenyl)-7-(3-Morpholino propoxy)-6-nitroquinazolin-4-aMine is a chemical compound belonging to the quinazoline class. It features a quinazoline core with a 6-nitro substitution, a 3-chloro-4-fluorophenyl group attached at one end, and a 3-Morpholino propoxy group at the other end. N-(3-chloro-4-fluorophenyl)-7-(3-Morpholino
propoxy)-6-nitroquinazolin-4-aMine holds potential pharmaceutical applications due to its unique structure, which may confer biological activity useful in the development of drugs for various medical conditions.
Uses
Used in Pharmaceutical Development:
N-(3-chloro-4-fluorophenyl)-7-(3-Morpholino propoxy)-6-nitroquinazolin-4-aMine is used as a potential active pharmaceutical ingredient for the development of drugs targeting various medical conditions. Its specific application in drug development would be guided by its biological activity, which may include:
Cancer Treatment: N-(3-chloro-4-fluorophenyl)-7-(3-Morpholino
propoxy)-6-nitroquinazolin-4-aMine may be utilized in the creation of anticancer drugs, leveraging its potential to interact with cellular processes and inhibit tumor growth.
Antibacterial Agents: It could be developed into antibacterial medications, targeting specific bacterial infections by disrupting essential cellular functions or inhibiting bacterial growth.
Anti-inflammatory Medications: Given its structure, the compound might be effective in reducing inflammation, making it a candidate for the treatment of inflammatory diseases.
Used in Research and Development:
In the scientific community, N-(3-chloro-4-fluorophenyl)-7-(3-Morpholino propoxy)-6-nitroquinazolin-4-aMine serves as a subject for research to explore its chemical properties, potential interactions with biological systems, and its efficacy and safety in treating specific conditions. This research is crucial for understanding the compound's full potential and for guiding its application in drug development.
Check Digit Verification of cas no
The CAS Registry Mumber 267243-64-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,6,7,2,4 and 3 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 267243-64:
(8*2)+(7*6)+(6*7)+(5*2)+(4*4)+(3*3)+(2*6)+(1*4)=151
151 % 10 = 1
So 267243-64-1 is a valid CAS Registry Number.
InChI:InChI=1/C21H21ClFN5O4/c22-16-10-14(2-3-17(16)23)26-21-15-11-19(28(29)30)20(12-18(15)24-13-25-21)32-7-1-4-27-5-8-31-9-6-27/h2-3,10-13H,1,4-9H2,(H,24,25,26)
267243-64-1Relevant articles and documents
Quinazoline derivative, preparation method and pharmaceutical application thereof
-
Paragraph 0034-0035, (2020/04/17)
The invention discloses a quinazoline derivative, a preparation method and pharmaceutical application thereof. The invention provides the quinazoline derivative which is a compound shown as formula Iin the specification, and also provides a pharmaceutical
6-Oxooxazolidine–quinazolines as noncovalent inhibitors with the potential to target mutant forms of EGFR
Shao, Jiaan,Chen, En,Shu, Ke,Chen, Wenteng,Zhang, Guolin,Yu, Yongping
, p. 3359 - 3370 (2016/07/20)
Despite the remarkable benefits of gefitinib, the clinical efficacy is eventually diminished due to the acquired point mutations in the EGFR (T790M). To address this unmet medical need, we demonstrated a strategy to prepare a hybrid analogue consisting of the oxooxazolidine ring and the quinazoline scaffold and provided alternative noncovalent inhibitors targeting mutant forms of EGFR. Most of the derivatives displayed moderate to good anti-proliferative activity against gefitinib-resistant NCI-H1975. Some of them exhibited potent EGFR kinase inhibitory activities, especially on EGFRT790Mand EGFRL858Rkinases. SAR studies led to the identification of a hit 9a that can target both of the most common EGFR mutants: L858R and T790M. Also, 9a displayed weaker inhibitory against cancer cell lines with low level of EGFR expression and good chemical stability under different pH conditions. The work presented herein showed the potential for developing noncovalent inhibitors targeting EGFR mutants.
Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase
Hur, Wooyoung,Velentza, Anastasia,Kim, Sungjoon,Flatauer, Laura,Jiang, Xinnong,Valente, David,Mason, Daniel E.,Suzuki, Melissa,Larson, Brad,Zhang, Jianming,Zagorska, Anna,DiDonato, Michael,Nagle, Advait,Warmuth, Markus,Balk, Steven P.,Peters, Eric C.,Gray, Nathanael S.
supporting information; experimental part, p. 5916 - 5919 (2009/06/25)
Irreversible HER/erbB inhibitors selectively inhibit HER-family kinases by targeting a unique cysteine residue located within the ATP-binding pocket. Sequence alignment reveals that this rare cysteine is also present in ten other protein kinases including all five Tec-family members. We demonstrate that the Tec-family kinase Bmx is potently inhibited by irreversible modification at Cys496 by clinical stage EGFR inhibitors such as CI-1033. This cross-reactivity may have significant clinical implications.
